Stocks TelegraphStocks Telegraph
Stock Ideas

BMRN Financial Statements and Analysis

NASDAQ : BMRN

BioMarin Pharmaceutical Inc.

$62.87
0.43+0.69%
At Close 4:00 PM
$63.25
0.38+0.60%
Pre-Market 07:00 PM
55.05
B-ESG ScoreESG Rating

BMRN FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

BMRN Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue745.74M708.658M648.833M646.207M585.965M
cost of revenue188.457M144.758M139.478M135.478M140.426M
gross profit557.283M563.90M509.355M510.729M445.539M
gross profit ratio0.7470.7960.7850.790.76
research and development expenses184.901M183.787M204.987M206.25M191.314M
general and administrative expenses144.60M140.232M0141.80M102.10M
selling and marketing expenses108.90M122.80M0133.20M121.90M
selling general and administrative expenses253.48M276.654M222.506M275.024M231.395M
other expenses5.009M-4.527M204.987M-15.236M4.047M
operating expenses443.39M460.441M427.493M496.51M422.709M
cost and expenses631.847M605.199M566.971M631.988M563.135M
interest income18.053M19.785M19.365M18.044M15.74M
interest expense2.968M3.574M3.547M6.098M3.779M
depreciation and amortization19.006M26.463M27.35M26.861M25.685M
ebitda156.415M162.173M136.444M41.08M48.515M
ebitda ratio0.210.1830.1680.0640.083
operating income113.893M103.459M81.862M14.219M22.83M
operating income ratio0.1530.1460.1260.0220.039
total other income expenses net20.548M11.684M17.085M5.108M18.839M
income before tax134.441M132.136M105.547M19.327M41.669M
income before tax ratio0.180.1860.1630.030.071
income tax expense28.361M24.962M16.885M-1.048M1.291M
net income106.08M107.174M88.662M20.375M40.378M
net income ratio0.1420.1510.1370.0320.069
eps0.570.560.470.110.21
eps diluted0.550.550.440.110.21
weighted average shs out190.429M190.114M188.866M188.479M188.219M
weighted average shs out dil197.147M200.505M199.262M191.838M191.173M
Graph

BMRN Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents675.448M972.15M746.996M755.127B785.414M
short term investments254.996M252.201M299.584M318.683M340.431M
cash and short term investments930.444M1.224B1.047B1.074B1.126B
net receivables777.547M691.232M637.163M633.704M572.498M
inventory1.179B1.184B1.138B1.107B1.032B
other current assets169.26M160.426M163.287M141.391M224.806M
total current assets3.057B3.26B2.985B2.956B2.955B
property plant equipment net1.045B1.053B1.06B1.066B1.067B
goodwill196.199M196.199M196.199M196.199M196.199M
intangible assets260.92M265.533M279.653M294.701M302.476M
goodwill and intangible assets457.119M461.732M475.852M490.90M498.675M
long term investments561.985M567.738M620.551M611.135M548.002M
tax assets1.531B1.545B1.546B1.546B1.524B
other non current assets199.314M180.117M184.79M171.538M165.069M
total non current assets3.795B3.807B3.888B3.886B3.803B
other assets001.0000
total assets6.851B7.067B6.873B6.842B6.758B
account payables312.321M257.412M292.238M683.147M301.369M
short term debt15.551M505.526M502.931M493.877M493.398M
tax payables21.04M18.864M6.071M2.651M11.273M
deferred revenue2.346M1.912M-593.543M-1.742B-301.369M
other current liabilities371.891M283.623M281.509M683.147M669.825M
total current liabilities715.658M1.067B1.088B117.702M1.163B
long term debt594.627M594.116M593.605M593.095M592.586M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities127.514M119.369M117.352M119.935M105.457M
total non current liabilities722.141M713.485M710.957M713.03M698.043M
other liabilities01.0001.059B0
capital lease obligations8.06M10.689M8.574M38.124M9.324M
total liabilities1.438B1.781B1.799B1.89B1.861B
preferred stock00000
common stock191.00K190.00K190.00K189.00K188.00K
retained earnings-319.638M-425.718M-532.892M-621.554M-641.929M
accumulated other comprehensive income loss4.65M15.126M-12.746M-28.788M6.257M
other total stockholders equity5.728B5.697B5.608B5.602B5.532B
total stockholders equity5.413B5.286B5.074B4.952B4.897B
total equity5.413B5.286B5.074B4.952B4.897B
total liabilities and stockholders equity6.851B7.067B6.873B6.842B6.758B
minority interest00000
total investments816.981M819.939M299.584M929.818M888.433M
total debt602.687M1.10B1.088B1.087B1.086B
net debt-72.761M127.492M340.966M-754.04B300.57M
Graph

BMRN Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax13.707B1.252M285.00K-24.844M-15.029M
stock based compensation149.546B47.914M58.249M54.855M48.387M
change in working capital172.307M-66.921M-105.386M-97.116M39.919M
accounts receivables-130.40B-52.695M-3.386M-58.495M13.891M
inventory-29.212B-30.589M-16.82M-59.11M-41.472M
accounts payables68.073B4.745M-59.006M12.52M81.426M
other working capital14.556M11.618M-26.174M7.969M-13.926M
other non cash items-150.863B182.259M169.972M47.352M-3.694M
net cash provided by operating activities387.048B118.762M46.971M27.483M135.646M
investments in property plant and equipment-65.838B-21.839M-34.104M-36.696M-23.419M
acquisitions net000024.064M
purchases of investments-352.176B-73.797M-121.665M-141.453M-282.994M
sales maturities of investments478.118B186.116M131.533M113.186M260.614M
other investing activites-94.00M111.807M10.00M1.00-24.064M
net cash used for investing activites60.011B90.48M-14.236M-64.963M-45.799M
debt repayment-60.00K-18.00K-42.00K-45.00K-606.00K
common stock issued-36.618M29.421M7.197M14.805M4.355M
common stock repurchased66.739M-16.791M-49.948M0-4.537M
dividends paid0000-4.537M
other financing activites-529.306B-16.791M-49.948M-3.92M4.537M
net cash used provided by financing activities-529.276B12.612M-42.793M10.84M-788.00K
effect of forex changes on cash395.70M3.30M1.927B47.04M1.974M
net change in cash674.476B225.154M-8.131M-30.287M91.033M
cash at end of period675.448B972.15M746.996M755.127M785.414M
cash at beginning of period972.15M746.996M755.127M785.414M694.381M
operating cashflow387.048B118.762M46.971M27.483M135.646M
capital expenditure-65.838B-21.839M-34.104M-36.696M-23.419M
free cash flow321.21B96.923M12.867M-9.213M112.227M
Graph

Frequently Asked Questions

How did BioMarin Pharmaceutical Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, BMRN generated $745.74M in revenue last quarter, while its costs came in at $188.46M.

Last quarter, how much Gross Profit did BioMarin Pharmaceutical Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. BioMarin Pharmaceutical Inc. reported a $557.28M Gross Profit for the quarter ended Sep 30, 2024.

Have BMRN's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. BMRN incurred $443.39M worth of Operating Expenses, while it generated $113.89M worth of Operating Income.

How much Net Income has BMRN posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from BioMarin Pharmaceutical Inc., the company generated $106.08M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did BioMarin Pharmaceutical Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to BioMarin Pharmaceutical Inc. as of the end of the last quarter was $675.45M.

What are BMRN's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, BMRN had Total Net Receivables of $777.55M.

In terms of Total Assets and Current Assets, where did BioMarin Pharmaceutical Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of BMRN were $3.06B, while the Total Assets stand at $6.85B.

As of the last quarter, how much Total Debt did BioMarin Pharmaceutical Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of BMRN's debt was $602.69M at the end of the last quarter.

What were BMRN's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, BMRN reported total liabilities of $1.44B.

How much did BMRN's Working Capital change over the last quarter?

Working Capital Change for BMRN was $172.31M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

BMRN generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. BMRN generated $387.05B of Cash from Operating Activities during its recently reported quarter.

What was BMRN's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. BMRN reported a $674.48B Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph